10-Q: Gyre Therapeutics Reports Net Income of $14.5 Million in First Half of 2024, Driven by Commercial Operations in China

Sentiment:

Quarterly Report 13 August 2024 4:05 PM

Gyre Therapeutics reported a net income of $14.5 million for the first six months of 2024, despite a decrease in revenue compared to the same period last year, primarily due to normalized anti-fibrosis drug sales.

Better than expectedThe company reported a net income of $14.5 million for the first half of 2024, a significant improvement compared to the $8.0 million net income for the same period in 2023.

Summary

Gyre Therapeutics reported a net income of $14.5 million for the first six months of 2024, compared to $8.0 million for the same period in 2023.
The company's revenue for the first half of 2024 was $52.4 million, a slight decrease from $54.3 million in the first half of 2023.
The decrease in revenue was primarily due to normalized sales of the anti-fibrosis drug ETUARY, which saw a temporary surge in 2023 due to COVID-19.
Operating expenses decreased slightly, with selling and marketing expenses down by $3.8 million, and research and development expenses down by $0.7 million.
General and administrative expenses increased by $3.4 million due to costs associated with being a public company.
The company's cash and cash equivalents stood at $16.1 million as of June 30, 2024, with an accumulated deficit of $74.5 million.
Gyre Therapeutics has a 65.2% indirect interest in Gyre Pharmaceuticals, a commercial-stage biopharmaceutical company in China.
The company is developing F351, a structural derivative of ETUARY, for the treatment of liver fibrosis, with a Phase 3 trial ongoing in China and a Phase 2a trial planned for the US in 2025.
Gyre Pharmaceuticals also acquired the rights to nintedanib, another drug for idiopathic pulmonary fibrosis, and received approval for avatrombopag for thrombocytopenia associated with chronic liver disease.

Sentiment

Score: 7

Explanation: The document shows positive financial results with a significant increase in net income, and progress in clinical trials and product acquisitions. However, there are some concerns about decreased revenue and increased administrative costs. Overall, the sentiment is positive but with some caution.

Positives

The company achieved a net income of $14.5 million in the first half of 2024, indicating profitability.
Operating expenses decreased, particularly in selling and marketing and research and development.
Gyre Pharmaceuticals expanded its product portfolio by acquiring the rights to nintedanib and receiving approval for avatrombopag.
The company is progressing its F351 development program with a Phase 3 trial ongoing in China and plans for a Phase 2a trial in the US.
The company has a strong cash position with $16.1 million in cash and cash equivalents.

Negatives

Revenue decreased slightly compared to the same period last year, primarily due to normalized sales of ETUARY.
General and administrative expenses increased significantly due to costs associated with being a public company.
The company has an accumulated deficit of $74.5 million.
The company experienced a decrease in net cash from operating activities, with $2.6 million used in the first half of 2024.

Risks

The company is subject to risks associated with dependence on key individuals, competition, uncertainty of clinical results, and ability to obtain adequate financing.
The company's cash and deposits at commercial banks in China exceed the amount protected by the Deposit Insurance System.
A significant portion of the company's revenue is concentrated with three customers in China.
The RMB is not a freely convertible currency, and its value is subject to changes in government policies.
The company's ability to use its net operating loss carryforwards may be limited due to ownership changes.
The company is subject to restrictions on foreign exchange and cross-border cash transfers in China.
The company is subject to claims and legal proceedings that arise in the ordinary course of business.

Future Outlook

The company expects to use cash flows from operations to meet its current and future financial obligations, including funding operations and capital expenditures. Management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the company's operating activities and obligations for at least 12 months following the filing date of this report. The company plans to submit an IND application for F351 in the US in late 2024 and initiate a Phase 2a trial for non-alcoholic steatohepatitis-associated liver fibrosis in 2025.

Management Comments

Management believes that existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund the Company's operating activities and obligations for at least 12 months following the issuance of these condensed consolidated financial statements.
Our strategy is to use our experience in the successful development and commercialization of ETUARY (Pirfenidone) to expand into new indications and develop similar drug candidates.
With this acquisition, we acquired a second product approved for the treatment of idiopathic pulmonary fibrosis and expect to provide patients more choices and benefits, and further enhance Gyre Pharmaceuticals leading position in the pulmonary fibrosis market.

Industry Context

Gyre Therapeutics operates in the biopharmaceutical industry, focusing on the development and commercialization of drugs for organ fibrosis. The company's focus on anti-inflammatory and anti-fibrotic drugs aligns with the growing need for treatments for fibrotic diseases, which represent a large patient population with significant unmet medical needs. The acquisition of nintedanib and the approval of avatrombopag position the company to compete in the pulmonary fibrosis and thrombocytopenia markets, respectively. The company's strategy of leveraging its experience with ETUARY to develop new drug candidates is a common approach in the industry.

Comparison to Industry Standards

Gyre's revenue of $52.4 million for the first half of 2024 is relatively modest compared to larger pharmaceutical companies, but it is a significant achievement for a company of its size and stage.
The company's focus on organ fibrosis is a growing area of interest in the pharmaceutical industry, with several companies developing treatments for similar conditions.
The company's strategy of developing structural derivatives of existing drugs, such as F351, is a common approach in the industry to reduce development risk and time.
The company's clinical trial progress for F351 is in line with industry standards for drug development, with a Phase 3 trial ongoing in China and a Phase 2a trial planned for the US.
The acquisition of nintedanib and the approval of avatrombopag are significant milestones for the company, positioning it to compete with other companies in the pulmonary fibrosis and thrombocytopenia markets.
Compared to companies like Boehringer Ingelheim and Roche, which also have approved IPF treatments, Gyre is a smaller player but is showing strong growth potential in the Chinese market.
The company's financial performance, with a net income of $14.5 million, is a positive sign, but it needs to continue to manage its expenses and grow its revenue to achieve long-term sustainability.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director and Chair of the Audit Committee	Nassim Usman, Ph.D.	NA	June 30, 2024	Resignation
Class II Director and Member of the Audit Committee and Compensation Committee	NA	David Epstein, Ph.D.	August 6, 2024	Appointment
Audit Committee Chair	NA	Rodney Nussbaum	August 6, 2024	Appointment

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Audit Committee Composition	The company was not in compliance with Nasdaq's audit committee composition requirements following the resignation of a director, but regained compliance with the appointment of a new director.	June 30, 2024	Temporary non-compliance with Nasdaq listing rules, resolved with the appointment of a new director.

Legal Proceedings

The Company is currently not a party to any material legal proceedings.

Related Party Transactions

Research and development fees paid to GNI during three and six months ended June 30, 2024 were $0.1 million.
As of June 30, 2024 and December 31, 2023, the Company had $1.5 million and $1.4 million related parties payable due to GNI.
As of June 30, 2024 and December 31, 2023, the Company had recorded $1.3 million in other receivables from GNI.

Stakeholder Impact

Shareholders: The company's improved financial performance and progress in clinical trials are positive for shareholders.
Employees: The company's growth and expansion may lead to new opportunities for employees.
Customers: The company's expanded product portfolio may provide more treatment options for patients.
Suppliers: The company's increased manufacturing activities may lead to increased business for suppliers.
Creditors: The company's improved financial position may reduce the risk for creditors.

Next Steps

The company plans to submit an IND application for F351 in the US in late 2024.
The company expects to initiate a Phase 2a trial for F351 in non-alcoholic steatohepatitis-associated liver fibrosis in 2025.
The company is preparing for the anticipated launch of the clinical trial in the PRC for F230.
The company will continue to monitor the results of the ongoing Phase 3 trial for F351 in China, with results expected by early 2025.
The company will continue to commercialize ETUARY and launch avatrombopag in China.

Key Dates

Date	Description
March 7, 1997	Gyre Therapeutics, Inc. was originally incorporated in Delaware under the name Targacept, Inc.
May 2015	A new Deposit Insurance System (DIS) managed by the People's Bank of China was implemented.
September 2020	Gyre Pharmaceuticals entered into an intellectual property transfer agreement with GNI Japan for F351.
October 15, 2021	Catalyst entered into an Equity Distribution Agreement with Piper Sandler & Co.
June 2021	Gyre Pharmaceuticals acquired avatrombopag under a transfer agreement with Nanjing Healthnice Pharmaceutical Technology, Co., Ltd.
December 26, 2022	Catalyst Biosciences, Inc. entered into a Business Combination Agreement.
January 5, 2023	Date used to determine CVR holders.
March 29, 2023	Amendment to the Business Combination Agreement and CVR Agreement.
August 30, 2023	Second Amendment to the Business Combination Agreement.
October 27, 2023	Gyre entered into a Securities Purchase Agreement for a private placement with GNI USA.
October 30, 2023	The Contributions became effective, and Catalyst acquired an indirect controlling interest in Gyre Pharmaceuticals.
November 2023	GNI USA provided notice to the Company to convert its 13,151 shares of Convertible Preferred Stock.
January 1, 2024	Additional shares of common stock were reserved under the 2023 Omnibus Incentive Plan.
January 22, 2024	8,767,333 shares of common stock were issued to GNI USA upon conversion of preferred stock.
April 2024	Gyre Pharmaceuticals entered into a lease arrangement for its new corporate headquarters in Beijing.
May 2024	Gyre Pharmaceuticals executed a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to acquire the rights to nintedanib.
May 2024	Gyre obtained approval from the PRCs National Medical Products Administration (NMPA) for the IND to launch a new clinical trial in the PRC of F230.
June 2024	Gyre Pharmaceuticals received approval from the NMPA for avatrombopag maleate tablets.
June 28, 2024	Gyre Pharmaceuticals entered into a partnership agreement with other investors.
June 28, 2024	Nassim Usman, Ph.D. resigned from the Board of Directors.
June 30, 2024	End of the reporting period for the quarterly report.
July 2, 2024	Gyre received a letter from Nasdaq confirming that it is no longer in compliance with Nasdaqs audit committee composition requirements.
July 17, 2024	Gyre Pharmaceuticals paid the initial investment to the partnership.
August 6, 2024	Gyre appointed a new Audit Committee Chair, Rodney Nussbaum.
August 6, 2024	The Board appointed David Epstein, Ph.D. as a Class II director.
August 9, 2024	Gyre informed Nasdaq that it regained compliance with Nasdaqs audit committee composition requirements.

Keywords

Gyre Therapeutics, biopharmaceutical, ETUARY, Pirfenidone, F351, liver fibrosis, pulmonary fibrosis, nintedanib, avatrombopag, China, clinical trials, net income, revenue, operating expenses, research and development

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.